OF
TRVI icon

Optimize Financial’s Trevi Therapeutics TRVI Stock Holding History

Optimize Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$380K Sell
31,890
-29,593
-48% -$331K 0.19% 204
2025
Q4 		$770K Buy
61,483
+884
+1% +$10.2K 0.39% 58
2025
Q3 		$554K Buy
+60,599
New +$454K 0.29% 96

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Optimize Financial's TRVI Position: Q1 2026 in Review

Optimize Financial reduced its Trevi Therapeutics (TRVI) stake by 48% in Q1 2026, selling an estimated $331K and leaving 31,890 shares worth $380K. The position accounts for 0.19% of the portfolio, ranked #204.

Optimize Financial first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. The position peaked at $770K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Optimize Financial held 31,890 shares of Trevi Therapeutics worth $380K as of Q1 2026.
  • Optimize Financial sold 29,593 Trevi Therapeutics shares in Q1 2026, an estimated $331K.
  • Trevi Therapeutics made up 0.19% of Optimize Financial's portfolio in Q1 2026, its #204 holding.
  • Optimize Financial first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optimize Financial's Trevi Therapeutics position peaked at $770K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.